A clinical-stage biopharmaceutical firm developing novel therapies for neurological conditions with substantial R&D investments and a negative net income driven by operating losses.
Investors may consider this stock if they believe in the transformative potential of its neurological drug pipeline and expect significant milestone payments or licensing deals to emerge from strategic partnerships. The company's substantial cash balance offers a buffer against near-term losses, allowing management flexibility to advance candidates without immediate equity dilution. A successful clinical readout could re-rate the entire asset portfolio at a much higher valuation multiple.
The negative operating profit of -$65.9M and widening net loss trend suggest that the company is burning cash rapidly with no visible path to commercial revenue generation in the near term. High general and administrative expenses relative to revenue indicate potential inefficiencies or scaling challenges common in small-cap biotechs struggling to transition from research to market. The significant retained earnings deficit of -$307.0M signals long-term profitability concerns that could lead to further dilution if external funding rounds are required.
Verrica Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological conditions, with its financial profile reflecting heavy investment in research and development typical of the sector. The company operates primarily through product discovery and development efforts, leveraging a pipeline of proprietary compounds aimed at treating unmet medical needs in neurology. With limited current revenue but significant cash reserves, the firm relies heavily on future commercialization success to achieve profitability.
The company reported a net loss of $76.6M in 2024, widening from the previous year's loss of $67.0M, primarily driven by operating expenses totaling $73.5M which include substantial general and administrative costs of $58.8M and research and development expenditures of $11.8M. Despite generating $7.6M in revenue, cash flow from operations turned negative at -$60.9M, indicating that the business is still in a cash-burning phase typical for clinical-stage biotechs. However, the firm maintains a healthy liquidity position with $46.3M in cash and equivalents against total liabilities of $64.0M, providing a runway to continue development activities.
The pharmaceutical industry, particularly the clinical-stage segment, is characterized by high failure rates in drug development and extended time horizons before commercialization can generate sustainable profits. Companies in this space often operate with negative earnings while investing heavily in research and development to secure first-mover advantages in specialized therapeutic areas like neurology. Success depends on navigating complex regulatory pathways and securing strategic partnerships or capital markets support to sustain operations through clinical trials.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $9.0M | $5.1M | $7.6M |
| Cost of Revenue | $0 | $500.0K | $2.6M |
| Gross Profit | $9.0M | $4.6M | $5.0M |
| Operating Expenses | $30.3M | $70.9M | $73.5M |
| Operating Income | $-21.3M | $-65.8M | $-65.9M |
| R&D | $12.2M | $20.3M | $11.8M |
| G&A | $17.4M | $47.3M | $58.8M |
| Stock-Based Comp | $5.0M | $14.4M | $7.2M |
| Depreciation | $454.0K | $530.0K | $342.0K |
| Other OpEx | $725.0K | $3.3M | $2.8M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $2.2M | $4.0M | — |
| Interest Income | $476.0K | $2.7M | $1.4M |
| Pre-Tax Income | $-21.3M | $-65.8M | $-65.9M |
| Income Tax | $3.2M | $0 | $0 |
| Continuing Ops | $-24.5M | $-65.8M | $-65.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-24.5M | $-67.0M | $-76.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-24.5M | $-67.0M | $-76.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $39.1M | $77.5M | $51.2M |
| Cash & Equivalents | $34.3M | $69.5M | $46.3M |
| Accounts Receivable | — | $4.2M | $48.0K |
| Inventory | — | $1.0M | $2.5M |
| Prepaid Expenses | $4.4M | $2.5M | $2.3M |
| Other Current Assets | $487.0K | $168.0K | $29.0K |
| Long-Term Assets | $5.6M | $4.1M | $3.0M |
| PP&E (Net) | $3.9M | $1.1M | $589.0K |
| Operating Leases | $1.4M | $1.2M | $836.0K |
| Other LT Assets | $276.0K | $1.9M | $1.5M |
| Total Assets | $44.7M | $81.6M | $54.1M |
| Current Liabilities | $3.5M | $17.0M | $29.0M |
| Accounts Payable | $507.0K | $2.5M | $1.9M |
| Current Debt | — | — | $12.9M |
| Current Leases | $297.0K | $324.0K | $315.0K |
| Other Current Liab | $2.7M | $14.2M | $13.9M |
| Long-Term Liabilities | $1.2M | $44.8M | $35.0M |
| LT Operating Leases | $1.2M | $910.0K | $583.0K |
| Other LT Liab | $0 | $43.9M | $34.4M |
| Total Liabilities | $4.7M | $61.8M | $64.0M |
| Shareholders' Equity | $40.0M | $19.8M | $-9.9M |
| Retained Earnings | $-163.5M | $-230.4M | $-307.0M |
| AOCI | $0 | — | — |
| Treasury Stock | $0 | $0 | $0 |
| Total L&E | $44.7M | $81.6M | $54.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-24.5M | $-67.0M | $-76.6M |
| Non-Cash Adjustments | $6.0M | $23.2M | $19.6M |
| Working Capital Changes | $-146.0K | $5.2M | $-4.0M |
| Cash from Operations | $-18.6M | $-38.6M | $-60.9M |
| Capital Expenditures | $302.0K | $362.0K | $27.0K |
| Cash from Investing | $54.0M | $-362.0K | $-19.0K |
| Cash from Financing | $-16.9M | $74.2M | $37.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $18.5M | $35.3M | $-23.2M |
| Beginning Cash | $15.8M | $34.3M | $69.5M |
| Ending Cash | $34.3M | $69.5M | $46.3M |
The company's operations are concentrated in research and development of proprietary drug candidates, general administration and overhead costs, and strategic partnerships or licensing activities that may contribute to revenue streams not fully detailed in standard product categories.
Clinical trial failure risk for late-stage assets, reliance on external funding due to negative operating cash flow and significant retained earnings deficit, potential dilution from equity issuance, and regulatory approval uncertainties for novel neurological therapies.
Proprietary intellectual property portfolio in neurology, specialized scientific expertise in drug discovery, and a streamlined organizational structure that minimizes operational overhead compared to large-cap peers.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.